Let's Talk Risk! Podcast

A qualified tool does not eliminate regulatory scrutiny. It eliminates the need to keep proving that the same ruler works.

What if one of the biggest sources of friction in medical device development is not the device itself—but the tool being used to measure its performance?
Historically, FDA evaluated many of these tools as part of individual device submissions. The Medical Device Development Tools (MDDT) program creates a different pathway: qualify a tool for a defined context of use, and sponsors can rely on that qualification in subsequent device development and regulatory submissions without having to repeatedly establish the tool’s suitability for that same use.
This Deep Dive explores what that means for evidence generation, regulatory strategy, and medical device development.
Key highlights covered in the audio:
* Why MDDT exists: reducing repeated evaluation of the same measurement and assessment methods across device submissions.
* Context of use is everything: qualification applies only within clearly defined boundaries for how, where, and for what purpose the tool is used.
* Different forms of evidence: qualified tools can include clinical outcome assessments, biomarker tests, non-clinical assessment models, and other specialized tools.
* From patient-reported outcomes to computational models: examples show how FDA is qualifying increasingly diverse ways of generating evidence.
* A more predictable development strategy: the MDDT process allows developers to establish the scientific credibility of a tool before relying on it in future regulatory decisions.
The important point is that MDDT qualification does not replace evaluation of the medical device itself.
Instead, it can reduce uncertainty around something equally important: whether the method being used to generate the evidence is scientifically credible for its intended purpose.
Keywords:
FDA MDDT, Medical Device Development Tools, Context of Use, Regulatory Science, Clinical Outcome Assessments, Biomarker Tests, Non-Clinical Assessment Models, Computational Modeling, Evidence Generation, Medical Device Development
🎧Listen to the Deep Dive for a closer look at how FDA’s MDDT program can reduce repeated validation work, improve predictability, and change how medical device teams think about evidence-generation strategy.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026). Medical Device Development Tools (MDDT) Program Guidance & Qualified Tools Registry (CDRH-FD&C Act Section 507).
* FDA (2024). Summary of Evidence and Basis of Qualification (SEBQ) for Apple Atrial Fibrillation History Feature. Apple AFib History Feature SEBQ Document (PDF)
* FDA (2024). Premarket Approval Application (PMA) Review for Abbott Medical’s TriClip G4 System. FDA Advisory Committee Review Presentation (PDF)
* FDA (2020). CDRH Qualification of the Kansas City Cardiomyopathy Questionnaire (KCCQ) as a Clinical Outcome Assessment Instrument.Listed in the FDA MDDT Qualified Tools Registry
* FDA (2026). Qualification of MolecuLightDX Wound Measurement as a Medical Device Development Tool. MolecuLightDX MDDT Qualification Announcement


This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

If you’re trying to manage risk in isolated silos, your quality management system is already obsolete.

What happens when a supplier changes a device label without triggering design controls? When operators quietly rework nonconforming product? Or when serious post-market signals never make it back into the risk file?
This Deep Dive examines recent FDA inspection and warning-letter examples through one common lens: the integration of risk management across the quality system.
The cases illustrate how seemingly separate failures in supplier controls, manufacturing, complaints, nonconforming product, CAPA, and infrastructure can become connected risk-management failures under QMSR.
Key highlights covered in the audio:
* Why ISO 13485 Clause 7.1 is becoming so important — and how risk management increasingly connects multiple parts of the QMS.
* Supplier changes can become risk-management events when labeling, intended use, or other product assumptions change without adequate escalation.
* Undocumented shop-floor rework can hide risk signals, leaving management metrics looking healthy while process problems accumulate.
* CAPA cannot work in isolation when environmental controls, process data, nonconformances, and risk analyses are disconnected.
* A static risk file is no longer enough. Post-market experience, manufacturing changes, supplier issues, and emerging hazards must continually inform lifecycle risk management.
The broader lesson is straightforward: QMSR is pushing companies away from managing compliance clause by clause and toward managing risk as an interconnected system.
And that raises an important question for medical device organizations:
When a new signal appears anywhere in your quality system, can it actually find its way back to the assumptions in your risk analysis?
Keywords:
QMSR, ISO 13485, ISO 14971, Risk Management, FDA Warning Letters, CAPA, Supplier Controls, Nonconforming Product, Design Changes, Lifecycle Risk Management
🎧 Listen to the Deep Dive for a closer look at what recent FDA QMSR warning letters reveal about the growing expectation to integrate risk management across the entire quality system.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026). Warning Letter to Koven Technologies, Inc. (MARCS-CMS 734643).
* FDA (2026). Warning Letter to Linemaster Switch Corporation (MARCS-CMS 730215).
* FDA (2026). Warning Letter to Nipro Renal Solutions USA, Corporation (MARCS-CMS 732874).
* FDA (2026). Medical Device Inspection Citations Data (2025–2026 Log), Regulatory Inspection Dataset (Form FDA 483 Observations).


This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

FDA: There is no reason to restrict the continued use of fluoropolymers in medical devices.
What happens when pressure to eliminate a material creates greater risk for the patient?
This Deep Dive examines the growing regulatory tension around PFAS and medical-device fluoropolymers, and why evaluating substitution requires more than asking whether a material belongs to a broad chemical category.
Key highlights covered in the audio:
* Not all PFAS present the same risk. The discussion distinguishes small-molecule PFAS from large, biostable fluoropolymers such as PTFE and PVDF used in medical devices.
* FDA’s position is supported by extensive clinical experience. Decades of use and a large ECRI review found no conclusive evidence of patient harm from PTFE.
* Substitution can introduce new clinical hazards. Changes in friction, flexibility, chemical resistance, sealing, or coating integrity can directly affect device performance and patient safety.
* This creates a substitution risk paradox. Eliminating one perceived material hazard may introduce more immediate risks such as reduced trackability, altered drug delivery, particulate shedding, or embolic complications.
* The decision belongs inside risk management. Under ISO 14971, the key question is how substitution changes the device’s total risk profile—not simply whether the original material can be removed.
* A defensible strategy requires evidence. Chemical characterization, toxicological assessment, clinical evidence, and post-market surveillance can support continued use of a proven material.
Keywords:
PFAS, Fluoropolymers, PTFE, Medical Devices, FDA, Material Substitution, ISO 14971, Benefit-Risk Assessment, Patient Safety, Risk Management
🎧 Listen to the Deep Dive for a closer look at why eliminating a perceived material hazard does not necessarily reduce the overall risk of a medical device.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026). PFAS in Medical Devices: What You Need to Know, FDA Web Resource, U.S. Food and Drug Administration
* Regulatory Affairs Group (2026). EU PFAS Restriction for Medical Devices: REACH Timelines and Derogations, Strategic Industry Report, MedTech Regulatory Guide


This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

Patient preference is no longer a soft qualitative afterthought.
What if a device carries significant risks, but patients are willing to accept them for a meaningful clinical benefit?
This Deep Dive examines how FDA’s evolving approach to Patient Preference Information (PPI) can turn those tradeoffs into quantitative evidence for regulatory benefit-risk decisions.
Key highlights covered in the audio:
* PPI is not the same as a patient-reported outcome. PROs describe what patients experience. PPI asks what risks patients are willing to accept to obtain a particular benefit.
* Risk tolerance can be quantified. Methods such as discrete choice experiments and threshold techniques can establish measures such as Maximum Acceptable Risk (MAR) and help define the level of benefit patients consider meaningful.
* Study design matters enormously. Patient comprehension, health numeracy, neutral presentation of risk, attribute selection, statistical analysis plans, and appropriate visual communication can determine whether preference data are credible.
* FDA engagement needs to happen early. The discussion highlights the importance of using the Q-Submission process to align on attributes, ranges, methodology, and statistical analysis before the study is conducted.
* PPI can extend beyond premarket approval. Preference information may inform labeling, shared decision-making, post-market benefit-risk assessments, and other decisions across the total product lifecycle.
Keywords:
Patient Preference Information, FDA Guidance, Benefit-Risk Assessment, Risk Tolerance, Medical Devices, Discrete Choice Experiment, Maximum Acceptable Risk, Q-Submission, Total Product Lifecycle, Risk Management
🎧 Listen to the Deep Dive for a closer look at how patient preference is becoming part of the quantitative language of medical-device risk management.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026, March 30). Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle, FDA Guidance Document, U.S. Food and Drug Administration
Pure Global (2026, April 8). FDA 2026 Guidance on Voluntary Patient Preference Information, Strategic Industry Report, Pure Global


This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

The vulnerability of the modern clinical lab is quite literally concentrated at the point of the needle.
Clinical laboratories have automated almost everything after the blood reaches the tube. Yet one of the most common invasive procedures in healthcare still depends on a person finding a vein by sight and touch and manually inserting a needle.
FDA’s De Novo authorization of Vitestro’s Aletta® may signal that this last major manual bottleneck is beginning to change.
But this Deep Dive is about much more than a robot drawing blood.
It explores a bigger question for anyone working in risk management, quality, regulatory, clinical, or medical-device development.
What does it take to make an autonomous medical device safe enough to perform an invasive clinical procedure on its own?
In this audio brief, we unpack how Aletta combines imaging, robotics, software constraints, clinical supervision, and layered fail-safes — and how FDA evaluated a technology for which no predicate existed before.
The result is a fascinating case study in how risk management changes when a machine begins doing what previously required a trained human.
Key highlights covered in the audio:
* De Novo pathway: De Novo authorization was necessary because there was no existing predicate for autonomous robotic phlebotomy.
* Risk controls built around autonomy: imaging, software constraints, movement detection and supervisory intervention create multiple layers of protection.
* Clinical performance: the ADOPT study reported a 94.5% first-stick success rate when a suitable vein was identified, including strong performance in patients with obesity and difficult venous access.
* Specimen quality: robotically collected samples demonstrated analytical equivalence for the laboratory parameters evaluated.
* Patient acceptance: 90% reported similar or less pain than manual phlebotomy, while 82% preferred the robotic system or had no preference.
* A different workforce model: FDA-authorized use allows one trained phlebotomist to supervise up to three devices simultaneously.
Keywords:
FDA De Novo, Aletta, Vitestro, autonomous medical devices, robotic phlebotomy, artificial intelligence, medical robotics, risk management, clinical evidence, human oversight, diagnostic testing, automation
🎧Click Play above to listen to a brief audio summary about this groundbreaking technology.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* Giesen LFP, Roest JA, et al. (2026, April 14). Performance, Safety, and Patient Experience of an Autonomous Robotic Phlebotomy Device: A Multicenter Trial, Clinical Chemistry (hvag029), Oxford Academic
* FDA (2026, August 19). FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device, FDA News Release, FDA
* Evidence-Based Medical Insight (2026, August 19). Clinical, Regulatory, and Operational Analysis of the Aletta Autonomous Robotic Phlebotomy System: A New Paradigm in Preanalytical Automation, Evidence-Based Medical Insight
* Bristow, H. (2026, May 27). Robotic Phlebotomy Trial: What the Patients Said, The Pathologist


This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe